Do genes influence on hypotensive respons in essential hypertension treatment?;Czy geny maja̧ wpływ na odpowiedź hipotensyjna̧ w leczeniu nadciśnienia tȩtniczego?

Nadcisnienie Tetnicze

Volumn 8, Issue 5, 2004, Pages 355-363

  Jankowska, Karolina ^a,b   Głuszek, Jerzy ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Klinika Nadcisnienia Tetniczego   (Poland)

Author keywords

Antihypertensive treatment; Arterial hypertension; Gene polymorphism

Indexed keywords

ADDUCIN; ANTIHYPERTENSIVE AGENT; BETA 1 ADRENERGIC RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA; GUANINE NUCLEOTIDE BINDING PROTEIN BETA3; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE THERAPY; DRUG RESPONSE; ESSENTIAL HYPERTENSION; GENE FUNCTION; GENETIC POLYMORPHISM; HUMAN; HYPOTENSION; LIFESTYLE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

EID: 11144337175     PISSN: 14285851     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Annest J.L., Sing C.F., Biron P. i wsp. Familial aggregation of blood pressure and weight in adoptive families. Am. J. Epidemiol. 1979; 110: 479-491.
2. Ciechanowicz A. Wprowadzenie do genetyki molekularnej nadciśnienia tȩtniczego. Pol. Arch. Med. Wew. 2001; 105: 103-108.
3. Gimenez-Roqueplo A.P., Jeunemaitre X. Genetics and essential hypertension: candidate genes or screening of the whole genome? Arch. Mal. Coeur Vaiss. 2003; 96: 1089-1095.
4. Hollenberg N.K. One's grandparents as the determinant of effective antihypertensive therapy. Blood Press Monit. 1999; 4 (supl. 1): S15-S18.
5. Kalow W. Pharmacogenetics of drug metabolism. Pergamin. Press Inc. New York 1992: 689-810.
6. Zee R.Y.L., Lou Y.K., Lyn R., Morris B.J. Association of a polymorphism of the angiotensin I-converting enzyme gene with essential hypertension. Biochem. Biophys. Res. Comm. 1992; 184: 9-15.
7. Stolarczyk D., Chmara E., Mrozikiewicz P.M., Brokl B., Mrozikiewicz A. Polimorfizm genu ACE w wybranej populacji Wielkopolski. Post. Farmakoter. 2000; 4: 26-27.
8. Harrap S.B., Davidson H.R., Connor J.M. i wsp. The angiotensin I converting enzyme gene and predisposition to high blood pressure. Hypertension 1993; 21: 455-460.
9. Malik F.S., Lavie C.J., Mehra M.R., Milani R.V., Re R.N. Renin-angiotensin system: Genes to bedside. Am. Heart J. 1997; 134: 514-526.
10. Matsubara M., Suzuki M., Fujiwara T. i.wsp. Angiotensin-converting enzyme I/D polymorphism and hypertension: the Ohasama study. J. Hypertens. 2002; 20: 1121-1126.
11. Schunkert H., Hense H.W., Holmer S.R. i wsp. Association between a deletion polymorphism of the angiotensin-converting enzyme gene and left ventricular hypertrophy. N. Engl. J. Med. 1994; 330: 1634-1638.
12. Iwai N., Ohmichi N., Nakamura Y., Kinoshita M. DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy. Circulation 1994; 90: 2622-2628.
13. Lindpaintner K., Pfeffer M.A., Kreutz R. i wsp. A prospective evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of ischaemic heart disease. N. Engl. J. Med. 1995; 332: 706-711.
14. Cambien F., Poirier O., Lecerf L. i wsp. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-644.
15. Reynolds M.V., Bristow M.R., Bush E.V. i wsp. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1073-1075.
16. Ferrara L.A., Guida L., Mangini F.P., Celentano A., Niano G.D. Structural and functional cardiovascular abnormalities in never-treated hypertensives according to ACE-gene polymorphism. J. Hum. Hypertens. 2003; 17: 441-443.
17. Ohishi M., Fujii K., Minamino T. i wsp. A potent genetic risk factor for restenosis. Nat. Genet. 1993; 5: 324-325.
18. Navis G., van der Kleij F.G.H., de Zeeuw D., de Jong P.E. Angiotensin-converting enzyme gene I/D polymorphism and renal disease. J. Mol. Med. 1999; 77: 781-791.
19. Stavroulakis G.A., Makris T.K., Krespi P.G. i wsp. Predicting response to chronic Antihypertensive treatment with fosi - the role of angiotensin- converting enzyme gene polymorphism. Cardiovasc. Drugs Ther. 2000; 14: 427-432.
20. Li X., Du Y., Du Y., Huang X. Correlation of angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by angiotensin-converting enzyme inhibitor. J. Cardiovasc. Pharmacol. Ther. 2003; 8: 25-30.
21. Ohmichi N., Iwai N., Uchida Y., Shichiri G., Nakamura Y., Kinoshita M. Relationship between the response to the angiotensin-converting enzyme inhibitor imidapril and the angiotensin-converting enzyme genotype. Am. J. Hypertens. 1997; 10: 951-955.
22. Hingorani A.D, Jia H., Stevens P.A., Hopper R., Dickerson J.E.C., Brown M.J. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J. Hypertens. 1995; 13: 1602-1609.
23. Dudley Ch., Keavney B., Casadei B., Conway J., Bird R., Ratcliffe P. Prediction of patient response to antihypertensive drugs using genetic polymorphism: investigation of renin-angiotensin system genes. J. Hypertens. 1996; 14: 259-262.
24. Kurland L., Melhus H., Karlsson J. i wsp. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J. Hypertens. 2001; 19: 1783-1787.
25. Svetkey L.P., Moore T.J., Simons-Morton D.G. i wsp. Angiotensinogen genotype and blood pressure response in the Dietary Approaches to Stop Hypertension (DASH) study. J. Hypertens. 2001; 19: 1949-1956.
26. Hiraga H., Oshima T., Watanabe M. i wsp. Angiotensin I-converting enzyme gene polymorphism and salt sensivity in essential hypertension. Hypertension 1996; 27: 569-572.
27. Giner V., Poch E., Bragulat E. i wsp. Renin-angiotensin system genetic polymorphism and salt sensivity in essential hypertension. Hypertension 2000; 35: 512-517.
28. Kojima S., Inenaga T., Matsuoka H. i wsp. The association between salt sensivity of blood presure and some polymorphic factors. J. Hypertens. 1994; 12: 797-801.
29. Gruchata M., Ciećwierz D., Sobiczewski W. i wsp. Brak zwia̧zku polimorfizmu genu receptora angiotensyny II typu 1 (ATI) z nadciśnieniem tȩtniczym i choroba̧ wieńcowa̧ u pacjentów poniżej 50 roku życia. Nadciśnienie Tȩtnicze 1997; 1: 111-116.
30. Bonnardeaux A., Davis E., Jeunemaitre X. i wsp. Angiotensin II type 1 receptor gene polymorphism in human essential hypertension. Hypertension 1994; 24: 63-69.
31. Rolfs A., Weber-Rolfs I., Regitz-Zagrosek V., Kallisch H., Riedel K., Fleck E. Genetic polymorphism of the angiotensin II type 1 (AT1) receptorgene. Eur. Heart J. 1994; 15 (supl. D): 108-112.
32. Miller J.A., Thai K., Scholey J.W. Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int. 1999; 56: 2173-2180.
33. Jeunemaitre X. Genetic polymorphisms in the rennin-angiotensin system. Therapie 1998; 53: 271-277.
34. Jeunemaitre X., Soubrier F., Kotelevtsev Y.V. i wsp. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992; 71: 169-180.
35. Kurland L., Liljedahl U., Karlsson J. i wsp. Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am. J. Hypertens. 2004; 17: 8-13.
36. Hunt S.C., Geleijnse J.M., Wu L.L., Witteman J.C.M., Williams R.R., Grobbee D.E. Enhanced blood pressure response to mild sodium reduction in subjects with the 235T variant of the angiotensinogen gene. Am. J. Hypertens. 1999; 12: 469-466.
37. Taymans S.E., Pack S., Pak E., Torpy D.J., Zhuang Z., Stratakis C.A. Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3. J. Clin. Endocrinol. Metab. 1998; 83: 1033-1036.
38. Brand E., Schorr U., Ringel J., Beige J., Distler A., Sharma A.M. Aldosterone synthase gene (CYP11B2) C-344T polymorphism in Caucasians from the Berlin Salt-Sensitivity Trial (BeSST). J. Hypertens. 1999; 17: 1563-1567.
39. Staessen J.A., Wang J.-G., Brand E. i wsp. Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. J. Hypertens. 2001; 19: 1349-1358.
40. Rossi E., Regolisti G., Perazzoli F., Negro A., Davoli S., Nicoli D. i wsp. -344C/T polymorphism of CYP11B2 gene in Italian patients with idiopathic low rennin hypertension. Am. J. Hypertens. 2001; 14: 934-941.
41. Tsukada K., Ishimitsu T., Teranishi M. i wsp. Positive association of CYP11B2 gene polymorphism with genetic predisposition to essential hypertension. J. Hum. Hypertens. 2002; 16: 789-793.
42. Tsujita Y., Iwai N., Katsuya T. i wsp. Lack of association between genetic polymorphism of CYP11B2 and hypertension in Japanese: the Suita Study. Hypertens. Res. 2001; 24: 105-109.
43. Kurland L., Melhus H., Karlsson J. i wsp. Aldosterone synthase (CYP11B2) -344C/T polymorphism is related to antihypertensive response: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am. J. Hypertens. 2002; 15: 389-393.
44. Ortlepp J.R., Hanrath P., Mevissen V., Kiel G., Borggrefe M., Hoffmann R. Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur. J. Pharmacol. 2002; 445: 151-152.
45. Hasimu B., Nakayama T., Mizutani Y. i wsp. Haplotype analysis of the human renin gene and essential hypertension. Hypertension 2003; 41: 308-312.
46. Soubrier F., Jeunemaitre X., Rigat B., Houot A.-M., Cambien F., Corvol P. Similar frequencies of renin gene restriction fragment length polymorphisms in hypertensive and normotensive subjects. Hypertension 1990; 16: 712-717.
47. Naftilan A.J., Williams R, Burt D. i wsp. A lack of genetic linkage of renin gene restriction fragment length polymorphisms with human hypertension. Hypertension 1989; 14: 614-618.
48. Bianchi G., Tripodi G., Casari G. i wsp. Two point mutations within the adducin gene are involved in blood pressure variation. Proc. Natl. Acad. Sci. 1994; 91: 3999-4003.
49. Cusi D., Barlassina C., Azzani T. i wsp. Polymorphisms of α-adducin and salt sensivity in patients with essential hypertension. Lancet 1997; 349: 1353-1357.
50. Kamitani A., Wong Z.Y., Fraser R. i wsp. Human alpha-adducin gene, blood pressure and sodium metabolism. Hypertension 1998; 32: 138-143.
51. Wang W.Y., Adams D.J., Glenn C.L., Morris B.J. The Gly460Trp variant of alpha-adducin is not associated with hypertension in white Anglo-Australians. Am. J. Hypertens. 1999; 12: 632-636.
52. Sugimoto K., Hozawa A., Katsuya T. i wsp. alpha-Adducin Gly460Trp polymorphism is associated with low renin hypertension in younger subjects in the Ohasama study. J. Hvpertens. 2002; 20: 1779-1784.
53. Ciechanowicz A., Widecka K., Drozd R., Adler G., Cyrylowski L., Czekalski S. Lack of association between Gly460Trp polymorphism of alpha-adducin gene and salt sensitivity of blood pressure in Polish hypertensives. Kidney Blood Press Res. 2001; 24: 201-206.
54. Beeks E., Kessels A.G., Kroon A.A., van der Klauw M.M., de Leeuw P.W. Genetic predisposition to salt-sensitivity: a systematic review. J. Hypertens. 2004; 22: 1243-1249.
55. Sciarrone M.T., Stella P., Barlassina C. i wsp. ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 2003; 41: 398-403.
56. Cusi D., Barlassina C., Taglietti M.V. Genetics of human arterial hypertension. J. Nephrol. 2003; 16: 609-615.
57. Sofowora G.G., Dishy V., Muszkat M. i wsp. A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin. Pharmacol. Ther. 2003; 73: 366-371.
58. Johnson J.A., Zineh I., Puckett B.J., McGorray S.P., Yarandi H.N., Pauly D.F. Beta1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin. Pharmacol. Ther. 2003; 74: 44-52.
59. Liu J., Liu Z.Q., Tan Z.R. i wsp. Gly389Arg polymorphism of betal-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin. Pharmacol. Ther. 2003; 74: 372-379.
60. O'Shaughnessy K.M., Fu B., Dickerson C., Thurston D., Brown M.J. The gain-of-function G389R variant of the β1-adrenoceptor does not influence blood pressure or heart rate response to β-blockade in hypertensive subjects. Clin. Sci. 2000; 99: 233-238.
61. sα gene with essential hypertension and response to β-blockade. Hypertension 1999; 34: 8-14.
62. Siffert W. G-protein beta3 subunit 825T allele and hypertension. Curr. Hypertens. Rep. 2003; 5: 47-53.
63. Siffert W., Rosskopf D., Erbel R. Genetic polymorphism of the G-protein beta3 subunit, obesity and essential hypertension. Herz 2000; 25: 26-33.
64. Benjafield A.V., Jeyasingam C.L., Nyholt D.R., Griffiths L.R., Morris B.J. G-protein beta3 subunit gene (GNB3) variant in causation of essential hypertension. Hypertension 1998; 32: 1094-1097.
65. 3-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001; 37: 739-743.
66. Arnett D.K., Boerwinkle E., Davis B.R., Eckfeldt J., Ford C.E., Black H. Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study. Pharmacogenomics J. 2002; 2: 309-317.